Page 1 Mark H. Einstein, C.V. CURRICULUM VITAE MARK H ... · CURRICULUM VITAE MARK H. EINSTEIN,...

Mark H. Einstein, C.V.

CURRICULUM VITAE

MARK H. EINSTEIN, M.D., M.S.

EDUCATION:

8/87 - 12/89 B.S., University of Miami, Biology

Biology Coral Gables, Florida

8/90 - 5/95 M.D. University of Miami School of Medicine

Miami, Florida -Graduated with Research Distinction in

Clinical Immunology

6/03-6/05 M.S. Clinical Research Methods- Graduated with Distinction,

Albert Einstein College of Medicine, Yeshiva University

POST GRADUATE TRAINING:

7/95 - 6/99 Resident, Obstetrics and Gynecology Saint Barnabas Medical Center.

Livingston, NJ

12/97 - 1/98 Galloway Fellow, Gynecologic Oncology Memorial Sloan-Kettering Cancer

Center. New York City, NY.

7/99 – 6/02 Fellow, Gynecologic Oncology Albert Einstein College of Medicine

and Montefiore Medical Center

PROFESSIONAL EMPLOYMENT AND HOSPITAL APPOINTMENTS

7/08-present Associate Professor, Department of Obstetrics & Gynecology and Women‟s

Health, Albert Einstein College of Medicine, Albert Einstein Cancer Center, and

Montefiore Medical Center.

8/09-present Associate Professor, Department of Epidemiology & Population Health

(Secondary appointment)

8/09-present Director of Clinical Research for Women‟s Health and Gynecologic Oncology,

Department of Obstetrics & Gynecology and Women‟s Health, Albert Einstein

College of Medicine, Albert Einstein Cancer Center, and Montefiore Medical

Center

7/07-present Tenure Track Appointment, Albert Einstein College of Medicine

6/05-present Director of Clinical Research, Division of Gynecologic Oncology, Department of

Obstetrics & Gynecology and Women‟s Health, Albert Einstein College of

Medicine, Albert Einstein Cancer Center, and Montefiore Medical Center

7/03-8/08 Director, Gynecologic Oncology Service, Jacobi Medical Center

1/03-7/08 Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics

& Gynecology and Women‟s Health, Albert Einstein College of Medicine and

Albert Einstein Cancer Center, Montefiore Medical Center

8/99-present Attending Physician, Department of OB/GYN, Jacobi Medical Center/North

Central Bronx Hospital.

7/99-12/02 Instructor, Division of Gynecologic Oncology, Department of Obstetrics &

Gynecology and Women‟s Health. Albert Einstein College of Medicine and

Montefiore Medical Center.

BOARD CERTIFICATION:

American Board of Obstetrics and Gynecology, General OB/GYN- Board Certified 12/03.


American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology- Board

Certified 4/05

Medical licenses in New York and New Jersey- Current; USMLE Step 1 - passed 1992, Step 2 -

passed 1994, Step 3 - passed 1996. ACLS, BLS - Current

PROFESSIONAL SOCIETY MEMBERSHIP:

American College of Obstetrics and Gynecology (ACOG) – Fellow

American College of Surgeons (ACS)- Fellow

Society of Gynecologic Oncologists (SGO)- Full Member

American Association for Cancer Research (AACR)- Full Member

American Society for Clinical Oncology (ASCO)- Full Member

American Society for Colposcopy and Cervical Pathology (ASCCP)- Member

HONORS AND AWARDS:

Associate Professor Henry L. Moses Competition in Clinical Medicine (for outstanding

publication amongst all Hospital Faculty)- Second Prize, 2010

American Cancer Society Research Scholar- Project: Epigenetic Deter-

minants of Progression to High Grade Cervical Neoplasia. 2008.

Henry L. Moses Competition in Clinical Medicine (for outstanding

publication amongst all Hospital Faculty)- First Prize, 2008

Assistant Professor Gynecologic Cancer Foundation Cervical Cancer Grant- Project: Role of

Genetic Variants in Cervical Cancer Risk. 2005.

American Professors in Gynecology and Obstetrics (APGO)/Ortho-

McNeil Faculty Development Award- Co-PI of project (with Dr.

N. Katz) entitled: Curriculum in Palliative and End-of-Life Care

for a Multi-Site OB/GYN and Women‟s Health Clerkship. 2005.

Henry L. Moses Competition in Clinical Medicine (for outstanding

publication amongst Hospital Faculty)- Second Prize, 2003.

CREOG National Faculty Award in Obstetrics and Gynecology for

Resident Teaching. 2003.

Fellowship ACOG/3M Pharmaceuticals Research Award in Lower Genital Infections-

Project: Serologic Response to Cervicovaginal HPV Infection,

7/01-6/02.

ACOG/Solvay Pharmaceuticals Research Award in Menopause- Project:

The Effects of Celecoxib, A Selective Cyclooxygenase-II Inhibitor,

on Endometrial Cancer. 7/02-6/03.

Berlex Oncology Foundation Scholar Award in Basic Science Research-

Project: Human Papillomavirus-Like Particle Serologic Assay to

Identify At-Risk Women. 7/02-6/03.

Residency Berlex Laboratories: Resident Teaching Award, 7/96-6/97

Top Resident Award in Colposcopy: American Society for Colposcopy

and Cervical Pathology, 1998

Elected as Administrative Chief for 1998-99.

Medical School Honors Program in Medical Education (accelerated six-year combined

M.D./B.S. program)


Eastern Student Research Forum: Awarded „Most Outstanding University

of Miami Clinical Presentation‟, 1992.

Clinical Honors awarded in Obstetrics, Gynecologic Oncology, Primary

Care, Colorectal Surgery, Geriatrics, and Pediatrics

J. Howard Greiner Award: Outstanding Achievement in Obstetrics and

Gynecology; Florida Obstetric and Gynecologic Society, 1995

OTHER PROFESSIONAL ACTIVITIES:

National and International Organization Leadership Roles

1/09-present Consultant World Health Organization (WHO), Develop Modules on

Immunologic Basis of HPV Vaccines

11/08-present Co-Chair Gynecologic Oncology Group (GOG) Immunotherapy

Subcommittee

1/11-present Member GOG Cancer Prevention Committee

11/08-present Member GOG Cervix Committee

10/10-present Member American Gynecological & Obstetrical Society (AGOS)

1/10-present Member, Board of American Society of Colposcopy and Cervical Pathology

Directors (ASCCP)

1/10-present Co-Chair, Practice American Society of Colposcopy and Cervical Pathology

Committee (ASCCP)

1/10-present Member, working ACS/ASCCP Cervical Cancer Screening Update 2011

Groups for writing

and data abstraction

3/10-present Chair GCF chair for SGO GynecoLogic Educational Materials for

Cervical Cancer and HPV

5/10-present Member The Cancer Genome Atlas (TGCA)/Cervical Disease

Working Group (DWG)

3/11-present Member Society of Gynecologic Oncologists (SGO) Marketing and

Communications Committee

11/08-3/11 Member Society of Gynecologic Oncologists (SGO) Education

Committee

12/09-present Member NIH Aids Malignancy Consortium, International Resource

Committee

1/10 SGO representative NCI/CDC US/Mexico Border Health Workshop (Cervix

Cancer Screening)

3/08-3/09 Member Program Committee, Society of Gynecologic Oncologists

(SGO) Annual Meeting

3/07-present Member, Board of Gynecologic Cancer Foundation (GCF)

Directors

7/06-present Co-Chair Gynecologic Cancer Working Group of the New York

Cancer Consortium (NYCC)

7/07-11/08 Member GOG Vaccine Subcommittee

6/05-6/06 Member American Cancer Society HPV Vaccine Expert Opinion

Panel

11/06-11/08 Chair Society of Gynecologic Oncologists (SGO) Physician

Education Awareness Campaign


11/06-11/08 Vice-Chair Society of Gynecologic Oncologists (SGO) Education

Committee

6/06-present Committee Chair Gynecologic Cancer Foundation (GCF) National Cervical

Cancer Education and Awareness Campaign.

4/05, 10/06 SGO Representative Translational Research Working Group (TRWG)

Roundtable, NIH/NCI

12/05-12/06 Reviewer 2006 International Union against Cancer (UICC) World

Congress Meeting-Cervical cancer

8/03-present Member NIH Aids Malignancy Consortium, HPV Working Group

3/03-present Member Gynecologic Cancer Foundation (GCF) Task Force for

National Cervical Cancer Screening and Prevention

6/05-present Member Educational Resource Panel/GynecoLogic Speaker‟s

Bureau for SGO for HPV-related issues

4/05-3/09 Member Society of Gynecologic Oncologists (SGO) Government

Relation‟s Committee

4/05-4/06 Member Society of Gynecologic Oncologists (SGO) Candidate

Member‟s Committee

3/02-3/04 Member Society of Gynecologic Oncology (SGO) Fellow‟s

Committee

Institutional and Local Committees/Membership

3/08-present Member Albert Einstein College of Medicine Oncology K12

Advisory Committee

10/07-present Member Albert Einstein College of Medicine Graduate Programs in

the Biomedical Sciences Qualifying Examination

Committee

12/05-present Member New York Phase II Consortium Executive Steering

Committee

7/05-present Co- PI Core Site, Aids Malignancy Consortium

8/04-present Member Albert Einstein General Clinical Research Center (GCRC)

Advisory Committee

4/04-present Member Albert Einstein Cancer Center Protocol Review Committee

1/03-present Member Albert Einstein Cancer Center

1/03-8/11 Member Albert Einstein Cancer Center Epidemiology, Immuno-

oncology, and Experimental Therapeutics Programs

8/02-2/04 Member Institutional Review Board (IRB)- Montefiore Medical

Center

Other Professional Activities

3/08-present Member External Advisory Committee Gynecology/Cervical

SPORE, Johns Hopkins

8/07-present Member New York State Cancer Consortium

Fellowship

8/01 Participant Berlex Oncology Foundation Clinical Epidemiology

Workshop


10/00 Participant Berlex Oncology Foundation Pharmacology in Oncology

Workshop

7/00 Participant AACR/ASCO Methods in Clinical Cancer Research

Workshop

3/00-2/01 Fellow Rep. Society of Gynecologic Oncology (SGO) Education

Committee

4/00 Participant Berlex Oncology Foundation Genetics in Oncology

Workshop

2/00, 2/02 Presenter Smith-Kline Beecham Fellow‟s Forum

10/99-present Volunteer First Saturday in October Program (provide breast and

cervical exams)

9/99 Participant SGO/NIH Granstmanship Conference

PEER REVIEWER:

Journals:

Obstetrics & Gynecology (commendation for being in top 10% of all Green Journal reviewers in

2008 and 2009), Gynecologic Oncology (awarded „Top Reviewer‟ status in 2010), Advances in

Therapy (Member, Advisory Board), Journal of Lower Genital Tract Diseases (member of

Editorial Board as of 2011), Journal of Infectious Disease, Clinical Cancer Research, Lancet

Infectious Diseases, Cancer Epidemiology, PLoS One, Biomarkers and Prevention, American

Journal of Epidemiology, American Journal of Obstetrics and Gynecology, Journal of Acquired

Immune Deficiency Syndromes, Journal of Surgical Oncology, Medical Oncology, International

Journal of Cancer, Anti-Infective Agents in Medicinal Chemistry Infectious Agents and Cancer,

Gynecologic and Obstetric Investigation, Expert Opinion on Biological Therapy, Obstetrics &

Gynecology International.

Grant review committees:

NCI/Division of Cancer Prevention- PREVENT Cancer Prevention Development Program

Special Emphasis Panel (SEP)/Study Section Member (2011-2014)

AHRQ Healthcare Horizon Scanning System Expert Reviewer (2011)

NIH/NCI Chemoprevention Agent Development Research Group to the Rapid Access to

Preventative Intervention Development (RAPID) program working group (2010)

Singapore Biomedical Research Council- Translational Clinical Sciences Group reviewer

(2010)

UK National Awareness and Early Diagnosis Initiative (NAEDI) project grant reviewer

(2010)

RESEARCH:

CURRENT FUNDING:

NIH/NCI R01 CA148966 (PI M. Einstein) 15%

Expanded Phase II Trial of Carraguard 8/1/10-5/30/16

For Prevention of HPV Infection


This is the first human trial using Carraguard, a microbicide that has been found to be active

against HPV in vitro, against HPV. This trial includes the Population Council, who has the IND

on Carraguard. Overlap: None

American Cancer Society (PI M.H. Einstein) 30%

Research Scholar Grant 08-002-01-CCE 1/1/08-12/31/11

Epigenetic Determinants of Progression to

High Grade Cervical Neoplasia This prospective trial will examine the outcomes in patients with biopsy-proven CIN 1 in Bronx, NY who are infected with HPV 16 and correlate these outcomes with epigenetic changes in the biopsies taken before and after the observation period. Overlap: None

NIH U01 CA83038 Co-PIs (J. Sparano, M.H. Einstein) 10%

Aids Malignancy Consortium (AMC) 6/1/06-5/31/12

Funding for AMC activities at one of the core AMC sites, Montefiore Medical Center.

Additionally, a member of the AMC HPV working group. PI of AMC protocols in HPV-related

diseases and local High Resolution Anoscopy physician for AMC protocols. Overlap: None

NIH/NCI D43 CA153793 (PI Anastos) 3%

Developing Rwandan Research Capacity 1/1/10-12/31/13

In Cervical Cancer and other AIDS Malignancies

This grant will support infrastructure for the ability to perform GCP clinical trials in Rwandan

women with HIV and/or cervical cancer. Overlap: None

NIH/NCI R01 CA133010 (PI M. Gunter) 10%

Role of Sex Hormone and Insulin/IGF Axes 6/01/09-5/31/13

in Endometrial Cancer Recurrence

This cohort investigation will examine the association of serologic and tissue components of the

sex hormone and Insulin/IGF axes with recurrence of high stage endometrial cancer in a well-

characterized population of endometrial cancer patients (Gynecologic Oncology Group Protocol

0210).

Overlap: None

NIH/NIAID U19 AI076980-04S1 (PI Herold) 5% (year 2)

Intravaginal Ring Delivery of Safe & Effective 7/1/11-6/30/13

Microbicides to Prevent HIV& HSV

The goal of this competitive revision is to conduct a pre-Phase I study to measure

pharmacokinetics, pharmacodynamics & safety of a TDF intravaginal ring. Overlap: None


NIH/NIAID R21/R33 AI079763 (PIs M Keller and B Herold) 5%

Novel Mucosal Models Predictive of Microbicide Safety 7/1/08-6/31/12 Applied translational study of a novel dual-chamber safety model using cervical tissue and a murine HSV-2 susceptibility model. If benchmarks are set, this tiered funding will be continued in HPV models. Overlap: None

NIH-NCI/NIAID WIHS Supplemental Funding (Herold) N/A

Unraveling the Mechanisms Underlying the Biologic 9/1/11-8/31/13

Synergy between HIV and HPV Disease

This is a supplement to the WIHS based off a pilot project done by a team with expertise in HPV

and HIV. The testing will be performed from banked WIHS specimens. Overlap: None

Albert Einstein Cancer Center/

Einstein Center for AIDS Research (CFAR) Pilot Project (PI Einstein) 5%

Epigenetic Determinants of High Grade CIN 3/1/10-2/27/12

And cancer in HIV-Infected and Uninfected Women

These pilot funds will be used to identify the epigenetic profiles in a cross-sectional population of

HIV-infected women with varying degrees of CIN and cervical cancer, when compared to their

HIV-uninfected counterparts. The methods for this have been determined through our ACS-

funded grant. Overlap: None.


Einstein Center for AIDS Research (CFAR) Pilot Project (PI K Anastos) In Kind

Diagnosing and tracking AIDS- 3/1/09-2/27/12

related malignancies in Rwanda

These pilot funds will be used to initiate development of a cancer registry through training Rwandans in best practices through the International Agency for Research on Cancer (IARC). Overlap: None


Einstein Center for AIDS Research (CFAR) Pilot Project (PI H Strickler) In Kind

Growth factor receptors as targets for treating 3/1/09-2/27/12

HPV-associated anogenital neoplasia in HIV-positive patients

These pilot funds will be used to identify the expression of IGF, EGFR, and VEGF-related expression in human HPV-associated anogenital cancers in HIV-infected patients. Overlap: None

PREVIOUS FUNDING:

NIH K12 RR017672 (PI H. Shamoon, Mentor R.D. Burk) 80%

K12 Career Development Award 7/1/03-6/30/07


Identification of Genetic Susceptibility

This is a career development during which time Dr. Einstein obtained a Master‟s Degree in

Clinical Research Methods through a K30-sponsored program (Clinical Research Training

Program). The goal of this project is to recruit patients with a family history of cervical cancer,

perform a genome-wide scan, and look for genetic susceptibility loci for patients with cervical

cancer.

NIH CFAR Supplemental Funding (PI K Anastos) 5% Capacity Building in cervical cancer 3/1/08-2/28/10 research in HIV-infected Rwandan Women The goals of this study is to establish a training program in cervical cancer screening within an infrastructure of HIV education and counseling already established in Rwanda through the primary partner the Rwandan Ministry of Health, as well as Women‟s Equity in Access to Care and Treatment (WE-ACTx Rwanda), the National University of Rwanda School of Public Health and Digene Corporation (Gaithersburg, MD, USA).

Mary Kay Ash Charitable Foundation Research Grant (PI K Dadachova) 5%

Targeting viral antigens with radiolabeled antibodies 07/01/08-06/30/10

as a novel approach to treatment of cervical cancer

This is a translational study of a novel radiolabeled HPV 16 antibody developed at Einstein and

will be tested in a cervical cancer heterotransplant mouse model

World Health Organization (WHO) 5%

Development of Modules on Immunologic 1/1/09-12/31/10

Basis of HPV Vaccines

This module is being developed as a WHO resource to vaccine policy-making leaders worldwide.

Dr. Einstein is a consultant to the WHO leading this effort.

NIH/CTEP Subcontract 24XS020 (PI A. Kadish) 5%

CTEP- Translational Research Initiative (TRI) 11/1/03-10/1/06

Immune Correlates for NCI 5850, „SGN-00101

(HspE7) Immunotherapy for Carcinoma-in-Situ of the Cervix‟.

The goals of this project were to determine the immune correlates to the CTEP study designed

and implemented by Dr. Einstein. The translational components were written by Dr. Mark

Einstein and Dr. Kadish, who is the PI of the TRI funding.

Gynecologic Cancer Foundation (GCF) (PI M.H. Einstein) 40%

Anonymous Cervical Cancer Grant 1/1/05-12/31/06

Role of Genetic Variants in Cervical Cancer Risk.

The primary goals of this study is to identify patients with HPV VLP seropositivity and CIN and

test for allelic polymorphisms in the transporter associated with antigen processing (TAP). We


hypothesize these polymorphisms facilitate disruption of antigen presentation, thus not allowing

them to clear their infection like those who are HPV VLP seropositive with no evidence of CIN.

American Professors in Gynecology and Obstetrics (PIs M.H. Einstein and N. Katz) 5%

Ortho/McNeill Faculty Development Award 1/1/05-12/31/06

Curriculum in Palliative and End-of-Life Care for a

Multi-Site OB-GYN & Women‟s Health Clerkship

This goal of this project was to develop curriculum in palliative and end-of-life care for medical

students during their 3rd

year clerkship.

American Medical Association (AMA) Foundation 5%

Seed Grant Research Program Mentor 7/1/07-6/30/09

Are Surgical Procedures Helpful in the Treatment

of Cervical Dysplasia in Poorly-Controlled HIV-Infected Women?

Dr. Einstein is a mentor to a medical resident (Dr. David Daniel) to identify within 2 large

hospital systems women with HIV who underwent a LEEP and determine HIV correlates of

treatment failure.

NIH Loan Repayment Program (LRP) L30 CA110417-01 N/A

Clinical Investigator 09/01/04-08/31/06

Provides payments for education loans.

NIH/NIAID 5P30AI051519 (PI M. Einstein) 10%

Center for AIDS Research (CFAR) Pilot Project 09/01/04-08/30/05

Immunotherapeutic approaches for management of

HPV–induced cervical neoplasia in HIV-infected women

This is a pilot study to validate correlative immune studies and obtain data to power a vaccine

trial in HIV-infected women with cervical dysplasia.

Berlex Oncology Foundation (PI M.H. Einstein) 50%

Scholar Award in Basic Science Research 07/01/02-06/30/03

Human Papillomavirus-Like Particle Serologic

Assay to Identify At-Risk Women.

This is a career development award with Dr. Einstein‟s Mentors (C.D. Runowicz and R.D. Burk).

The goal of this project is to study the serologic responses to type-specific HPV types in women

with cervical dysplasia.

American College of Obstetrics and Gynecology (ACOG)(PI M.H. Einstein) 30%

Award in Menopause Studies 04/1/03-10/1/05

A Pilot Phase II Trial of Celecoxib in Patients with

Grade 2 or 3 Endometrioid-type, Clear Cell and Papillary


Serous Uterine Cancers.

The study is an investigator-initiated and investigator-designed study by Dr. Mark Einstein with

translational components. Supplementary funds and drug over costs not funded were provided

by Pharmacia.

American College of Obstetrics and Gynecology (ACOG) (PI M.H. Einstein) 20%

Research Award in Lower Genital Infections 07/01/01-06/30/02

Serologic Response to Cervicovaginal HPV Infection

The goal of this project was to develop and refine a serologic assay to examine type-specific

HPV responses in women.

LEADERSHIP ROLE/GRANTS FOR MULTI-INSTITUTIONAL NIH-SPONSORED TRIALS

NCI #8167 „Pilot Phase II Study of Temsirolimus in Patients with Recurrent Mixed Mesodermal

and Mullerian Tumors (Carcinosarcoma) of the Uterus.‟ Dr. Einstein is the overall PI of this trial

and designed this trial with collaborators.

NCI #8223 „Phase 2 trial of CCI-779 and Bevacizumab in Endometrial, Carcinoid, Islet Cell,

Hepatocellular, and Ovarian Cancer‟. Dr. Einstein is the overall PI of the Endometrial

Component of this Multi-Consortium Trial and is helping with the design and management.

NCI #5840 „A Phase II Study of Oxaliplatin in combination with Paclitaxel in Patients with

locally Recurrent of Metastatic Cervical Cancer‟. Dr. Einstein designed this trial with co-PIs and

provided overall oversight for this trial.

GOG 276 ‘Targeting HPV E2 as a vaccine against HPV mediated CIN1 and CIN2‟. Dr. Einstein

is the Co-PI of this Gynecologic Oncology Group Trial. Translational components to be done by

NCI (Khlief lab)

AMC-081/NCI „Pilot Study of Safety, Toxicity, and Compliance of Concomitant

Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer‟. Dr. Einstein is the

lead PI of this AIDS Malignancy Consortium (AMC)/NCI-sponsored protocol. Concept

approved by AMC, pending protocol approval from CTEP.

AMC-052/NCI „A SingleArm, Open-Label Trial of the Safety and Immunogenicity of a

Quadrivalen Human Paillomavirus Vaccine in HIV-1-Infected Men‟. Dr. Einstein is one of the

lead PIs on this trial.

AMC-046/NCI „Phase IIA Trial of 1% Topical Cidofovir for Treatment of High Grade Perianal

Squamous Intraepithelial Lesions in HIV-1-Infected Men‟. Dr. Einstein is one of the lead PIs on

this trial.


GOG-8015/NCI „Role of Sex Hormone and Insulin/IGF Axes in Endometrial Cancer

Recurrence‟. Dr. Einstein is the Study Co-Chair of this correlary study trial that is funded by an

NCI R01.

NCI 5850 „SGN-00101 (HspE7) Immunotherapy for Carcinoma-in-Situ of the Cervix‟.

Clinicaltrials.gov unique identifier NCT00075569. Dr. Einstein submitted the letter of intent with

Dr. Carolyn Runowicz to the NCI and CTEP for the use of this investigational agent. He

designed and wrote the protocol with Dr. Runowicz. He is the Study chair for the consortium

participating in this protocol and the local principal investigator.

INVESTIGATOR-INITIATED CLINICAL TRIAL PROTOCOLS

„Pilot Phase II trial of Ifosfamide “Sandwiched” with Radiation Therapy for the Treatment of

Mixed Mullerian Tumors of the Uterus‟. Clinicaltrials.gov unique identifier NCT00231842.

Role: Co-author and PI of this investigator-initiated and investigator-designed clinical trial.

„Pilot Phase II trial of Taxol and Carboplatin “Sandwiched” with Radiation Therapy for the

Treatment of Uterine Papillary Serous Carcinoma‟. Clinicaltrials.gov unique identifier

NCT00231868. Role: Co-author and PI of this investigator-initiated and investigator-designed

clinical trial.

„A Pilot Phase II Trial of Radiation Therapy “Sandwiched” between Paclitaxel and Carboplatin

in Patients with High-Risk Endometrial Cancer After Standard Surgical Staging‟.

Clinicaltrials.gov unique identifier NCT01041027. Co-author and supervising PI of this

investigator-initiated and investigator-designed clinical trial.

„Phase II Trial- Weekly Taxotere and Topotecan for Recurrent Ovarian, Primary Peritoneal,

Endometrial and Uterine Cancers‟. Clinicaltrials.gov unique identifier NCT00231855. Role:

This study was designed, written and submitted by the principal investigator, Dr. Mark Einstein.

„A Pilot Phase II Trial of Celecoxib in Patients with Grade 2 or 3 Endometrioid-type, Clear Cell,

and Papillary Serous Uterine Cancers‟. Clinicaltrials.gov unique identifier NCT00231829. Role:

This study was designed, written and submitted to the IRB by the principal investigator, Dr.

Mark Einstein. Dr. Einstein also performed the preclinical benchwork for this trial.

INVITED PRESENTATIONS:

Beth Israel Deaconess Medical Center Department of OB/GYN Louis Burke Lecture. Talk

entitled, „Changing Landscape of Cervical Cancer Prevention‟. September, 2011.

Columbia University OB/GYN Grand Rounds invited speaker. Grand rounds entitled, „Changing

Landscape of Cervical Cancer Therapy‟. August, 2011.

American College of Obstetricians and Gynecologists Annual Meeting 2011. Post-graduate

course faculty. “Update in Gynecologic Oncology- and the Impact for the Practicing

Gynecologist”. April, 2011.

Association for Clinical Research Training (ACRT)/AFMR/SCTS Joint Annual Meeting.


Workshop faculty on „Trajectories for success in clinical research: no one path fits all‟.

Talk entitled, „Clinical/translational research training for surgeon-scientists and other

time-consuming clinical specialties: lessons from the trenches‟. April, 2011.

Society of Gynecologic Oncology Annual Meeting 2011. Sunrise Session Course Faculty.

“Updates in HPV Vaccination”. March, 2011.

American College of Obstetricians and Gynecologists District 2 meeting. Lecture entitled

“Updates in HPV Vaccination”. October, 2010.

Hunterdon Medical Center Grand Rounds. Lecture entitled “The Changing Landscape of

Cervical Cancer Screening and Prevention”. October, 2010.

Gynecologic Oncology Group Semi-annual 2010 Meeting Summer Symposium Program.

Lecture entitled, „Optimizing translational research opportunities in cervical cancers‟.

July, 2010.

American College of Obstetricians and Gynecologists Annual Meeting 2010. Post-graduate

course “Update in Gynecologic Oncology- and the Impact for the Practicing

Gynecologist”. May, 2010.

Florida Society of Gynecologic Oncologists. Invited Lecture, „Immunotherapies for HPV-

associated Diseases. June 2010

Federation of Medical Women of Canada. Invited lecture, „Bi vs. Quad: Pros and Cons‟.

Toronto, CA. June, 2010.

Japanese Society of Obstetrics and Gynecology (JSOG) 2010. Symposium entitled „Updated

Status of Cervical Cancer Prevention with Vaccine‟- Lecture entitled „Immunogenicity

analyses of two prophylactic HPV cervical cancer vaccines at month 18‟. Tokyo, Japan.

2010.

Eurogin 2010 Cervical Cancer Prevention Meeting. Lecture Entitled, „Update of Comparative

Immunogenicty Trial Between The Bivalent and Quadrivalent HPV Vaccines‟. Monte

Carlo, Monaco. February 2010.

American Society for Colposcopy and Cervical Pathology (ASCCP) Biennial Meeting 2010.

Two invited lectures. „Chemoprevention and Novel Therapeutics Targeting Cervical

Dysplasia‟ and „Bi vs. Quad: Pros and Cons‟. Las Vegas, NV. March 2010.

Society of Gynecologic Investigation, Invited Speaker. „Controversies over HPV Vaccines‟.

Glasgow, Scotland. 3/09.

Course Director, Society of Gynecologic Oncologists (SGO) Annual Meeting. Course:

„Therapeutic Vaccines for Cervical Neoplasia‟. Feb., 2009.


Moderator, SGO Annual Meeting. Plenary Session, „HPV-Associated Diseases‟. Feb., 2009.

Lenox Hill Dept. of OB/GYN grand rounds. Lecture entitled, „HPV Therapeutic vaccines‟.

11/08

Cornell Dept. of OB/GYN grand rounds. Lecture entitled, „HPV Vaccines: Present and

Future‟. 1/09

St. Barnabas Medical Center, Livingston, NJ, Dept. of OB/GYN grand rounds. Lecture entitled,

„HPV Vaccines: Present and Future‟. 12/08

Lenox Hill Dept. of OB/GYN grand rounds. Lecture entitled, „HPV Vaccines: Present and

Future‟. 11/08

Moderator, Society of Gynecologic Oncologists Forum „The Future Strategies of Cervical

Cancer Prevention: What do We Need to Do Now to Prepare?‟. Chicago, IL. 9/08

Gynecologic Oncology Group Bi-Annual Meeting Scientific Session Speaker. „HPV/Adjuvant

Immunology Basics‟ and „Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS)-

Adjuvant in Gardasil ‟. Chicago, IL. 7/08.

Leukemia & Lymphoma Society Meeting, Invited Speaker. „Vaccines for Cervical Cancer:

Opportunities and Needs for New Research Initiatives‟. NY, NY. 4/08.

Society of Gynecologic Investigation, Invited Speaker. „HPV Vaccines: Present and Future‟.

San Diego, CA. 3/08.

St. Barnabas Hospital, Dept. of OB/GYN grand rounds. Lecture entitled, „HPV Vaccines:

Challenges and Opportunities for the Future‟. 2/08. „Gestational Trophoblastic Disease‟.

9/08

New York University, Dept. of OB/GYN grand rounds. Lecture entitled, „Cervical Cancer

Vaccines‟. 12/07.

University of Connecticut Cancer Center-Ella Grasso Conference. Lecture entitled, „Vaccines

and Cervical Cancer‟. 11/07.

American College of Obstetricians and Gynecologists (ACOG) District II Meeting. Lecture

entitled, „Vaccines and Cervical Cancer: Opportunities and Needs for New Research

Initiatives‟. 12/07.

Clinical Director‟s Network Webcast. Lecture entitled, „Vaccines and Cervical Cancer:

Opportunities and Needs for New Research Initiatives‟. 10/07.

Bronx OB/GYN Society. Lecture entitled, „New Developments in Cervical Cancer Prevention‟.

10/07.


NY State Department of Health. New York State Cancer Consortium Meeting. Lecture entitled,

Vaccines and Cervical Cancer. 6/07.

Lehman College- CUNY. Graduate School Lecture Series. Lecture entitled, „Vaccine Strategies

for HPV-Associated Cancers‟. 4/07.

Lenox Hill, Department of Medicine, New York City. Grand Rounds Lecture entitled, „Cervical

Cancer Prevention and Incidence Reduction in the Era of Prophylactic Vaccines‟. 3/07

Chemotherapy Foundation Symposium on Innovative Cancer Therapy for Tomorrow. Lecture

entitled, „Cervical Cancer Vaccines‟. 11/06.

National Coalition for Cancer Research Visit to Capitol Hill. „Cervical Cancer Prevention and

Reduction in the Era of Prophylactic Vaccine‟. 9/06.

American Cancer Society Physician Forum. St. Luke‟s-Roosevelt Hospital. Lecture

entitled, „HPV and the New Vaccine‟. 5/06.

Berlex Oncology Foundation Annual Retreat. Lecture entitled, „Human Papillomavirus- Like

Particle Assay to Identify Women At-Risk for Persistent HPV Infection‟. Sonoma, CA

9/03.

INVITED AECOM OR AECOM-AFFILIATE PRESENTATIONS

St. Barnabas Medical Center (Bronx, NY). Invited speaker for grand rounds, „Cervical Cancer

Prevention‟. 8/11

Einstein-Montefiore Institute for Clinical and Translational Research symposium entitled

„Translating Clinical Research into Better Health‟. Invited speaker „Cervical Cancer‟.

11/10.

Lincoln Medical Center Grand Rounds. Lecture entitled “Updates on HPV Vaccination”. 11/10.

Bronx Lebanon Grand Rounds. Lecture entitled “The Changing Landscape of Cervical Cancer

Screening and Prevention”. 10/10.

Albert Einstein College of Medicine Department of Obstetrics & Gynecology and Women‟s

Health Grand Rounds. Lecture Entitled, „Clinical and Translational Opportunities in

Female HPV-Associated Disease at Montefiore/Einstein‟. 8/10

Albert Einstein Cancer Center Grand Rounds. Lecture Entitled, „Clinical and Translational

Opportunities in Female HPV-Associated Disease at Montefiore/Einstein‟. 8/10

Montefiore/Albert Einstein Infectious Diseases Grand Rounds. Lecture entitled, „HPV

associated issues in HIV‟. 2/10


Albert Einstein Department of Radiation Oncology. Lecture entitled, „HPV Screening and

Prevention‟. 4/09

Beth Israel Medical Center- Manhattan. OB/GYN Resident Research Day Bitterman Lecturer.

Lecture Entitled, „HPV Vaccines: Present and Future‟. 6/08.

Phase II Consortium Meeting. Lecture entitled, „Torisel in MMMT of the Uterus‟. New York

Hospital, NY 1/08.

New York Cancer Consortium (NYCC) Developmental Therapeutics Symposium-Vaccines,

Immunotherapy, and Gene Therapy. Session Chair and Speaker. 5/07

Beth Israel Medical Center- Manhattan. OB/GYN Grand Rounds. Lecture Entitled, „The Future

of Cervical Cancer Screening, Prophylaxis and Treatment‟. 4/06.

North Shore Hospital Immunology Series. Lecture entitled, „Vaccine Strategies for HPV-

Associated Neoplasms‟. North Shore Hospital-Research Building. 6/05.

National Cancer Survivor‟s Day 2005. Lecture entitled, „The War on Cancer‟. Albert Einstein

College of Medicine. 6/05.

Albert Einstein Cancer Center Advances Retreat. Lecture entitled, „ Immunotherapy for

Cervical Neoplasia‟. Botanical Gardens, Bronx, NY. 5/04.

New York Phase II Consortium Meeting. Lecture entitled, „SGN-00101 (HspE7)

Immunotherapy for Carcinoma-in-Situ of the Cervix‟. New York Hospital, NY 2/04,

3/05.

Department of Obstetrics & Gynecology and Women‟s Health „Autumn in New York‟

Conference- Minimally Invasive Laparoscopy Laboratory. Instructor. 11/02.

BIBLIOGRAPHY

A. Original Communications in Reviewed Journals:

Einstein MH, Garcia FAR, Mitchell AL, Day SP. Performance of the Cervista®

Human

Papillomavirus 16/18 test Among Age-stratified Women With Atypical Squamous Cells of

Undetermined Significance Cytology. Cancer Epi Biomarkers Prev. May 17. 2011 (Epub

ahead of print)

Ho GYF, Einstein MH, Romney SL, Kadish AS, Abadi M, Mikhail M, Basu J, Thysen B, Palan

D, The Albert Einstein Cervix Dysplasia Clinical Consortium,* Burk RD. Risk Factors

for Persistent Cervical Intraepithelial Neoplasia Grade I and II Managed by Watchful

Waiting. J Low Genit Tract Dis. 2011. Epub ahead of print.

Wieland DL, Reimers LL, Wu E, Nathan LM, Gruenberg T, Abadi M, Einstein MH.

Performance of Implementing Guideline-Driven Cervical Cancer Screening in an Inner

City Hospital System. J Low Genit Tract Dis. 2011. In Press


Herzog TJ, Huh W, Einstein MH. How does public policy impact cervical screening and

vaccination strategies? Gynecol Oncol. 119(2): 175-80. 2010

Phaeton R, Harris M, Jiang Z, Wang XG, Einstein MH, Goldberg GL, Casadevall A,

Dadachova D. Radioimmunotherapy with antibody to HPV-16 E6 oncoprotein is

effective in experimental cervical cancer expressing low levels of E6. Cancer Biology

and Therapy. In press. 2010.

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn

DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM. Safety and Immunogenicity of

the quadrivalent HPV vaccine in HIV-1 infected men. Journal of Infectious Diseases.

202(8): 1246-53. 2010.

Einstein MH, Martens MG, Garcia FAR, Mitchell AL, Ferris DG, Mitchell AL, Day SP, Olson

MC. Clinical Validation of the Cervista® HPV HR Test and 16/18 Genotyping Tests for

Use in Cervical Cancer Screening. Gynecol Oncol. 118(2): 116-22. 2010.

Schwarz TF, Kocken M, Petäjä T, Einstein MH, Spaczynski M, Louwers JA, Pedersen C,

Levin M, Zahaf T, Poncelet S, Hardt K, Descamps D, Dubin G. Correlation between

Levels of Human Papillomavirus (HPV)-16 and -18 Antibodies in Serum and

Cervicovaginal Secretions with HPV-16/18 AS04-Adjuvanted Cervical Cancer Vaccine.

Human Vaccines. 6(12). 2010.

Reimers LL, Sotardi S, Daniel D, Chiu LG, Van Arsdale A, Wieland DL, Leider JM, Xue X,

Strickler HD, Einstein MH. Outcomes after an excisional procedure for cervical

intraepithelial neoplasia in HIV-infected women. Gynecol Oncol. 119(1):92-7. 2010.

Einstein MH, Phaeton R. Issues in cervical cancer incidence and treatment in HIV-infected

women. Current Opinion in Oncology. 22 (5): 449-55. 2010.

Stern PL, Einstein MH. From HPV Infection to oncogenesis: a brief review of the complex

immunobiological events. Current Cancer Therapy Reviews. 6(2): 110-116. 2010.

Downs L, Saraiya M, Einstein MH, Scarini I. Identifying specific barriers to HPV vaccination

in high-risk populations. Gynecol Oncol. 117(3): 486-90. 2010.

Kuo DY, Blank SV, Christos PJ, Kim M, Caputo TA, Pothuri B, Hershman D, Goldman N, Ivy

PS, Runowicz CD, Muggia F, Goldberg GL, Einstein MH. Paclitaxel plus oxaliplatin for

recurrent or metastatic cervical cancer: A New York Cancer Consortium study. Gynecol

Oncol. 116(3):442-6. 2010.

Huh W, Einstein MH, Franco E. What is the role of HPV typing in the United States now and in

the next five years in a vaccinated population? Gynecologic Oncology. 117(3): 481-5.

2010.


Phaeton R, Wang XG, Einstein MH, Goldberg GL, Casadevall A, Dadachova E. The influence

of proteasome inhibitor MG132, external radiation and unlabeled antibody on the tumor

uptake and biodistribution of 188

Re-labeled anti-E6 C1P5 antibody in cervical cancer in

mice. Cancer. 116(4 Suppl):1067-74. 2010.

Van Doorslaer K, Reimers LL, Studentsov YY, Einstein MH, Burk RD. Serological response

to an HPV 16 E7-based therapeutic vaccine in women with high-grade cervical

dysplasia. Gynecol Oncol. 116(2): 208-212. 2010.

Chudnoff S, Einstein MH, Levie M. The Efficacy of Paracervical Block in Office Hysteroscopic

Sterilization: A Randomized, Double-Blinded, Placebo-Control Study. Obstetrics and

Gynecology. 115(1):26-34. 2010.

Dicken CL, Lieman HJ, Dayal AK, Mutyala S, Einstein MH. A Multidisciplinary Approach to

Fertility Sparing Therapy for a Rare Vulvar Tumor. Fertility & Sterility. 93(1): 267.e5-7.

2010

Einstein MH, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F, Carletti I, Dessy F, Trofa

A, Dubin G, Schuind A, on behalf of the HPV-010 Study Group. Comparison of

neutralizing antibody and memory B-cell responses induced by Cervarix™ and

Gardasil®

human papillomavirus (HPV) cervical cancer vaccines in healthy women aged

18–45 years. Human Vaccines. 5(10): 705-19. 2009.

Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D.

Clinician‟s guide to HPV immunology: knowns and unknowns. Lancet Infectious

Diseases. 9(6):347-356. 2009.

Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey M, Gill GM,

Mettinger K, Mariadason JM, Mani S, Goel S. Intravenous administration of Reolysin(R),

a live replication competent RNA virus is safe in patients with advanced solid tumors.

Investigational New Drugs. 28(5): 641-9. 2010.

Gupta D, Owers RL, Kim M, Kuo DY, Huang GS, Shahabi S, Goldberg GL, Einstein MH. A

phase II study of weekly topotecan and docetaxel in heavily pretreated patients with

recurrent uterine and ovarian cancers. Gynecologic Oncology. 113(3):327-330. 2009.

Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D. The impact of

human papillomavirus vaccination on cervical cancer prevention efforts. Gynecologic

Oncology. Aug;114(2):360-4. Epub 2009 May 1. 2009.

Einstein MH, Leanza S, Chiu LG, Schlecht NF, Goldberg GL, Steinberg BM, Burk RD. Genetic

Variants in TAP are associated with High-Grade Cervical Neoplasia. Clinical Cancer

Research. 15(3): 1019-1023. 2009.

Einstein MH. Natural acquired immune response to oncogenic human papillomavirus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gollamudi%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ghalib%20MH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Desai%20KK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chaudhary%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wong%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Einstein%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Coffey%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gill%20GM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mettinger%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mariadason%20JM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mani%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Goel%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus


associated with prophylactic cervical cancer vaccines. Cancer Immunology

Immunotherapy. 57(4):443-451. 2008.

Dar P, Karmin I, Einstein MH. Arteriovenous Malformations of the Uterus: Long-Term Follow-

Up. Gynecol Obstet Invest. 66(3): 157-161. 2008.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Li J, Harris TG, Xue X, Rohan TE, Ho

GY, Einstein MH, Kaplan RC, Burk RD, Pollak MN, Howard B, Manson JE, and

Strickler HD. A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as

Risk Factors for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention.

Apr;17(4):921-9.2008.

Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL. Pilot Phase II Trial of Radiation

“Sandwiched” between combination Paclitaxel/Platinum Chemotherapy in Patients with

uterine papillary serous carcinoma (UPSC). Gynecol Oncol. 2008. Jan; 108(1): 201-6.

American Cancer Society Expert Opinion Panel (Leader: Debbie Saslow, PhD; Members in

Alphabetical Order: Castle P, Cox JT, Davey D, Einstein MH, Ferris D, Goldie S,

Harper D, Kinney W, Koutsky L, Markowitz L, Moscicki AB, Noller K, Wheeler C,

Partridge E, Garcia F. ACS Gudelines for HPV Prophylactic Vaccination. CA Cancer J

Clin. Jan-Feb;57(1):7-28. 2007.

Novetsky AP, Einstein MH, Goldberg GL, Hailpern SM, Horton F, Landau E, Mutyala S, Fields

AL, Garg G. Efficacy and toxicity of concomitant Cisplatin with external beam pelvic

radiotherapy and two High Dose Rate brachytherapy insertions for the treatment of

locally-advanced cervical cancer. Gynecol Oncol. 105(3):635-40. 2007.

Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Fields AL, Kalnicki S, Goldberg

GL. Survival and Toxicity Differences between 5-day and Weekly Cisplatin Concomitant

with External Beam Radiotherapy and High Dose Rate Brachytherapy in Patients

with Locally-Advanced Cervical Cancer. Cancer. 2007. Jan 1;109(1):48-53.

Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler SS, Streicher H, Goldberg GL, Runowicz

CD. Heat Shock Fusion Protein-Based Immunotherapy (HspE7) for Treatment of

Cervical Intraepithelial Neoplasia (CIN) III (NCI 5850). Gynecol Oncol. 2007. Sept.

106(3): 453-460.

Huang GS, Chiu L, Gebb J, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH. Serum

CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol

Oncol. 2007. Dec.; 107(3): 513-7.

Einstein MH, Studentsov YY, Ho G, Fazzari M, Marks MM, Kadish AS, Goldberg GL,

Runowicz CD, Burk RD. Human Papillomavirus-Like Particle Serologic Assay to

Identify Women At-Risk for High-Grade Cervical Intraepithelial Neoplasia. Int J Cancer.

120(1): 55-59. 2007.


Society of Gynecologic Oncologists Educational Resource Panel (Members in Alphabetical

Order: Collins Y, Einstein MH, Gostout B, Herzog TJ, Massad LS, Rader JS, Wright J).

Cervical Cancer Prevention in the Era of Prophylactic Vaccines: A Preview for

Gynecologic Oncologists. Gynecol Oncol. 102:552-62. 2006.

Huang GS, Gebb JS, Einstein MH, Shahabi S, Novetsky AP, Goldberg GL. Accuracy of Pre-

operative Endometrial Sampling for the Detection of High-Grade Endometrial Tumors.

Am J Obstet Gynecol. Mar;196(3):243.e1-5. 2007.

Goel S, Desai K, Karri S, Gollamudi R, Chaudary I, Bulgaru A, Kaubisch A, Goldberg G,

Einstein M, Camacho F, Baker S, Mani S. Pharmacokinetic and safety study of weekly

irinotecan and oral capecitabine in patients with advanced solid cancers. Invest New

Drugs. Dec 30. 2006. (Epub ahead of print).

Goldberg GL, Sukumvanich, P, Einstein, MH; Smith, HO; Anderson, PS; Fields, AL. Total

Pelvic Exenterration: The Albert Einstein College of Medicine/Montefiore Medical

Center Experience (1987 to 2003). Gynecol Oncol. 101 (2):261-8. 2006.

Goel S, Desai K, Macapinlac M, Wadler S, Goldberg GL, Fields AL, Einstein MH, Volterra F,

Wong B, Martin R, Mani S. A Phase I Safety and Dose Escalation Trial of Docetaxel

Combined With GEM 231, A Second Generation Antisense Oligonucleotide Targeting

Protein Kinase A R1a in Patients with Advanced Solid Cancers. Invest New Drugs.

Mar;24(2):125-34. 2006.

Sukumvanich P, Einstein MH, Wagner B, Gucalp R, Goldberg GL. Recurrent Small Cell Lung

Cancer Presenting as Adnexal Masses. Gynecol Oncol. 2005; Jan;96(1):232-4.

Kadish AS, Einstein MH. Vaccine Strategies for Human Papillomavirus-Associated Cancers.

Curr Opin Oncol. 2005; Sep; 17(5): 456-461.

Trambert J, Einstein MH, Banks E, Frost A, Goldberg GL. Use of Embolization for The

Primary Management of Cervical Pregnancy. J Reprod Med. 2005; Nov;50(11):844-50.

Einstein MH, Kadish AS. Anogenital Neoplasia in AIDS. Curr Opin Oncol. 2004

Sep;16(5):455-62.

Huang G, Einstein MH, Khabele D, Goldberg GL. Serum Tumor Biomarkers in Ovarian

Cancer. Women‟s Oncol Rev, 2003;3:117-122.

Einstein MH, Cruz Y, El-Awady MK, Popescu NC, DiPaolo JA, van Ranst M, Kadish AS,

Romney S, Runowicz CD, Burk RD. Utilization of the Human Genome Sequence

Localizes HPV 16 DNA Integrated Into The TNFAIP2 Gene in a Fatal Cervical Cancer

from a 39 Year Old Woman. Clinical Cancer Research, 2002; 8(2): 549-554.

Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R, Jones JG. Expression of COX-2,


Ki67, Cyclin D1 and p21 in Human Endometrioid Carcinomas. International Journal of

Gynecological Pathology. 2002; 21(2): 147-54.

Einstein MH and Goldberg GL. Human Papillomavirus and Cervical Neoplasia.

Cancer Investigation, 2002; 20(8): 1097-1102.

Levie M, Einstein MH and Goldberg GL. Cervical Intraepithelial Neoplasia: An Overview of

Diagnosis and Management. Cancer Investigation. 2002; 20(5): 1-8.

Einstein MH, Burk RD. Persistent Human Papillomavirus Infection: Definitions and Clinical

Implications. Papillomavirus Report. 2001; 12(5): 119-123.

Terrone D, Rinehart B, Einstein MH, Britt L, Martin J, Perry K. Neonatal Sepsis and Death

Due to Resistant E.Coli: Possible Consequences of Extended Maternal Ampicillin

Administration. Am J Obstet Gynecol. 1999; 180: 1345-1348.

Winner: Best Essay at the Central Association of Obstetricians and Gynecologists

Stabinsky, SA, Einstein MH, Breen JL. Modern Treatments of Menorrhagia Attributable to

Dysfunctional Uterine Bleeding. Obstet Gynecol Surv. 1999; 54: 61-72.

Einstein MH, Breen JL. Ephraim McDowell, The Father of Ovariotomy: A Historical

Perspective. J Pelvic Surg. 1999; 5: 317-319.

Denehy T, Einstein MH, Gregori C, Breen JL. Symmetrical Periumbilical Extension of a

Midline Incision: A Simple Technique. 1998; Obstet Gynecol. 91:293-294.

Allain JP, Hodges W, Einstein MH, Geisler J, Neilly C, Delaney S, Hodges B, Lee H.

Antibody To HIV-1, HTLV-1 and HCV in Three Populations of Rural Haitians. J

Acquired Immune Def Synd. 1992; 5:1230-1236.

Allain JP, Laurain Y, Einstein MH, Braun BP, Delaney SR, Stephens JE, Daluga CK, Dahlen

SJ, Knigge KM. Monitoring of Specific Antibodies to Human Immunodeficiency Virus

Structural Proteins: Clinical Significance. Blood. 1991; 77:1118-1125.

Manuscripts

Einstein MH, Frimer M, Kuo DYS, Reimers LL, Mehta K, Mutyala S, Huang GS, Hou JY,

Goldberg GL. Prospective phase II trial of adjuvant pelvic radiation “sandwiched”

between combination paclitaxel,carboplatin chemotherapy n women with uterine

papillary serous carcinoma. Manuscript under review.

Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, Reimers LL, Kuo DYS,

Huang GS, Goldberg GL. Phase II Trial of Adjuvant Pelvic Radiation “Sandwiched”

Between Ifosfamide or Ifosfamide plus Cisplatin in Women with Uterine

Carcinosarcoma. Manuscript under review.

B. Books, Chapters in Books and Invited Editorials:


Stern PL, Einstein MH. From HPV Infection to oncogenesis: a brief review of the complex

immunobiological events: 2011 update. Immunological Basis of HPV Infection. Editor:

Franco Borruto, Università degli Studi di Verona. Springer. In Press. 2011.

Einstein, MH. Immunological Basis of Human Papillomavirus Vaccines. Immunological Basis

for Immunization Series. World Health Organization. Geneva, Switzerland. In Press.

2011.

Sparano JA, Haigentz M Jr, Einstein MH. Targeting EGFR in HPV Associated Cancer.

Molecular Basis for Therapy of AIDS-Defining Cancers. Springer. In Press. 2010.

Einstein MH, Novetsky AP, Gupta D. Cervical Cancer- Etiology, Natural History,

Epidemiology, and Prophylaxis. Gynecologic Oncology: Requisites in Obstetrics and

Gynecology. Edited by David Fishman. Elsevier Press. In Press. 2009.

Einstein MH, Runowicz CD. Early Diagnosis and Screening for Ovarian Cancer. Diagnosis

and Management of Ovarian Disorders, Second Edition. Edited by Altchek A,

Deligdisch L, and Kase N. Academic Press. 2003.

Einstein MH. Venereal Disease in Pregnancy. Manual of Clinical Problems in Obstetrics and

Gynecology: 5th

Edition. Lippincott, Williams, and Wilkins. 1999.

Invited Editorial:

Berchuck A, Einstein MH. Forward for Gynecologic Oncology Supplement: New biomarkers

and risk predictors for prevention and early detection of gynecologic cancers. Gynecol

Oncol. 121(1):1. 2011.

Runowicz CD, Brewer M, Einstein MH. ACOG Update in „Understanding the new guidelines in

cervical and breast cancer screening‟. 2010.

Einstein MH (contributor). 2007 State of the State of Gynecologic Cancers: 5th

Annual Report

to Women of America. Gynecologic Cancer Foundation Publication. 2007.

Einstein MH (contributor). 2006 State of the State of Gynecologic Cancers: 4th

Annual Report

to Women of America. Gynecologic Cancer Foundation Publication. 2006.

Einstein MH. Cervical Cancer Screening in the Era of Improved Technology and HPV

Vaccines. OB/GYN News Supplement. Chair of supplement. 2007.

C. Abstracts and Presentations

Einstein MH, Belbin TJ, Abadi MA, Nathan LM, Goldberg GL, Strickler HD, Burk RD,

Schlecht NF. Prospectively Identified Epigenetic Signatures that Predict Clinical

Outcomes in CIN. Accepted as an Oral Presentation at the International Papillomavirus

Meeting 2011 Berlin, Germany.

Mhatre M, McAndrew T, Carpenter C, Burk RD, Herold BC, Einstein MH. CIN is Associated


with Changes in Genital Mucosal Immune Environment. Accepted as an Oral Poster

Presentation at the International Papillomavirus Meeting 2011 Berlin, Germany.

Stier E, Goldstone S, Einstein MH, Naomi J, Berry M, Wilkin T, Lee J, Panther L, Aboulafia D,

Palefsky J. Phase IIA Trial of 1% Topical Cidofovir for Treatment of High Grade

Perianal Squamous Intraepithelial Neoplasia in HIV-Infected Men and Women (AMC

046). Accepted as an Oral Presentation at the International Papillomavirus Meeting 2011

Berlin, Germany.

Garcia F, Nieminen P, Harper D, Donders G, Einstein MH, Huh WK, Calleja E, Leung M,

Clinch B. HPV Genotype Distribution in a Large HPV-Targeted Immunotherapeutic CIN

2/3 Trial. Accepted as a Poster Presentation at the International Papillomavirus Meeting

2011 Berlin, Germany.

Einstein MH on behalf of the HPV-010 Investigators. Comparison of immunogenicity of two

prophylactic human papillomavirus (HPV) vaccines at month 36. Plenary Presentation at

Eurogin 2011 Meeting in Lisbon, Portugal.

Einstein MH, Frimer M, Phaeton R, Reimers LL, Mehta K, Mutyala S, Kuo DY, Goldberg GL.

Phase II trial of radiation “sandwiched” between combination paclitaxel/carboplatin

chemotherapy in women with uterine papillary serous carcinoma (UPSC). Focused

Plenary Presentation at the SGO 2011 Annual Meeting.

Einstein MH, Belbin T, Adrien L, Goldberg GL, Strickler HD, Burk RD, Schlecht NF.

Prospective Identification of Epigenetic Signatures that Predict Regression in High-Risk

HPV Positive Early Cervical Intraepithelial Neoplasia. Featured Poster Presentation at

the SGO 2011 Annual Meeting.

Wu E, Wieland D, Reimers LL, Burton L, Gruenberg T, Abadi M, Einstein MH. Performance

of Implementing Guideline-Driven Cervical Cancer Screening in an Inner City Hospital

System. Featured Poster Presentation at the SGO 2011 Annual Meeting.

*Won Prize for Best Clinical Poster for SGO 2011 Annual Meeting

Hou Y, Smotkin D, Smith HO, Isani SS, Goldberg, GL, Einstein MH. High Incidence of Anal

Disease Diagnosed from Screening HIV-Infected Women. Poster Presentation at the

SGO 2011 Annual Meeting.

Ghartey JP, Einstein MH, Chazotte C, Herold BC. Soluble Mucosal Immune Mediators in the

Genital Tract of Pregnanty Women with Group B Streptococcus. Plenary Presentation at

the Society of Gynecologic Investigation 2011 Meeting.

Scott R, Dragoman M, Lorga S, Einstein MH. Contraceptive Use and Counseling in HIV-

Infected Women. Oral Presentation at the ACOG Annual Meeting 2011.

Murphy D, Reimers LL, Tugetman J, Kotak A, Phaeton R, Kuo D Y-S, Weiland D, Sartodi S,


Calderon Y, Keller M, Herold B, Einstein MH. HPV Microbicide Acceptibility Among

Women in an Urban Population. Poster presentation at the International Papillomavirus

Meeting Montreal CA. 2010.

Stier EA, Goldstone SE, Einstein MH, Jay N, Berry JM, Wilkin T, Lee J, Panther LA,

Aboulafia D, Palefsky JM. Phase IIA Trial of 1% Topical Cidofovir for Treatment of

High Grade Perianal Squamous Intraepithelial Neoplasia in HIV-Infected Men and

Women (AMC 046). Poster presentation at the International Papillomavirus Meeting

Montreal CA. 2010.

Einstein MH, Hou JY, Mutyala S, Lee SJ, Reimers LL, Kuo DY, Huang GS, Shahabi S,

Smotkin D, Goldberg GL. Phase II Efficacy and Toxicity of Sequential Ifosfamide or

Ifosfamide plus Cisplatin „Sandwiched‟ with Radiation Therapy as Adjuvant Therapy for

Patients with Surgically-Staged Carcinosarcoma. Poster presentation to 2010 Society of

Gynecologic Oncologists Annual Meeting. San Francisco, CA.

Harris M, Phaeton R, Jiang Z, Wang XG, Einstein MH, Goldberg GL, Dadachova E. Successful

treatment of experimental cervical cancer expressing low levels of HPV-16 oncogene

with radiolabeled antibody to E6. Poster presentation at the NCI/ESMO Targeted

Anticancer Therapy 2010 meeting. Bethesda, MD.

Harris M, Phaeton R, Jiang Z, Wang XG, Einstein MH, Goldberg GL, Dadachova E. The

contribution of unlabeled antibodies to intracellular antigens to efficacy of

radioimmunotherapy in experimental metastatic melanoma and cervical cancer. Poster

presentation at the 2010 AACR Meeting. Washington DC.

Gao W, Thawani N, Vainshtein JM, Kabarriti R, Yaparpalvi R, Mehta K, Einstein MH, Reimers

L, Kalnicki S, Mutyala S. Toxicity and Early Outcomes of Endometrial Carcinoma

treated with Intensity Modulated Radiation Therapy. Poster discussion session at the

American Society of Radiation Oncology Annual Meeting 2009.

Vainshtein JM, Thawani N, Gao W, Reimers L, Yaparpalvi R, Kabarriti R, Spierer MM,

Einstein MH, Kalnicki S, Mutyala S. Intensity Modulated Radiation Therapy (IMRT)

Reduces Hematologic Toxicity with Similar Disease Control and Survival Compared to

3D-Conformal Radiotherapy (CRT) in the Treatment of Uterine Papillary Serous

Carcinoma (UPSC) with Carboplatin and Paclitaxel Chemotherapy and Radiotherapy.

Poster discussion session at the American Society of Radiation Oncology Annual

Meeting 2009.

Thawani N, Kabarriti R, Gao W, Vainshtein JM, Yaparpalvi R, Mehta KJ, Skinner WJ, Einstein

MH, Kalnicki S, Mutyala S. Intensity Modulated Radiation Therapy (IMRT), High Dose

Rate Brachytherapy (HDR) and Weekly Cisplatinum (CDDP) for treatment of Locally

Advanced Cervical Cancer (LACC). Poster session at the American Society of Radiation

Oncology Annual Meeting 2009.

Einstein MH, Baron M, Levin M, Chatterjee A, Carletti I, Dessy F, Schuind A, Dubin G, on


behalf of the HPV-010 Study Group. Comparative Evaluation of Immungenicity of Two

Prophylactic Human Papillomavirus Cervical Cancer Vaccines. Poster presentation at

the European Society of Gynaecological Oncology (ESGO) 2009.

Herzog TJ, Rose PG, Braly PS, Hines JF, Bell MC, Wenham R, Alvarez-Secord A, Miller DS,

Edwards RP, Roman L, Einstein MH, Soltes-Rak E, Monk BJ. Oxaliplatin, Docetaxel,

and Bevacizumab as Front-Line Therapy of Advanced Cancer of the Ovary, Peritoneum,

and Fallopian Tube. Poster presentation at the European Society of Gynaecological

Oncology (ESGO) 2009.

Einstein MH on behalf of the HPV-010 Study Group. Comparative immunogenicity of two

prophylactic Human Papillomavirus cervical cancer vaccines: month 18 results. Late-

Breaker Poster Presentation at the 2009 Infectious Diseases Society of America Annual

Meeting, Philadelphia, PA.

Reimers LL, Daniel D, Sotardi S, Chiu LG, Van Arsdale A, Wieland DL, Leider JM, Garry DJ,

Gupta D, Goldberg GL, Strickler HD, Einstein MH. Are extirpative procedures for CIN

effective in HIV-positive women? Plenary Presentation at the 2009 International

Papillomavirus Meeting, Malmo, Sweden.

Einstein MH, Baron M, Levin M, Chatterjee A, Edwards R, Zepp F, Carletti I, Dessy F, Trofa

A, Schuind A, Dubin G, on behalf of the HPV-010 Study Group. Comparative

Immungenicity of The Prophylactic Human Papillomavirus Vaccines. Plenary

Presentation at the 2009 International Papillomavirus Meeting, Malmo, Sweden.

Reimers LL, Tugetman J, Ginsberg MS, Sandesara N, Kuo DY, Einstein MH.

Sociodemographic and HPV Risk Factor Assessment of Early-Adopting Users of the HPV

Vaccine in the Late Catch-Up Population (ages 19-26) in an Ethnically Diverse, Urban

Population. Poster Presentation at the 2009 International Papillomavirus Meeting,

Malmo, Sweden.

Van Doorslaer K, Reimers LL, Studentsov YY, Einstein MH, Burk RD,. Serologic Response to

an HPV 16 E7-base Therapeutic Vaccine. Poster Presentation at the 2009 International

Papillomavirus Meeting, Malmo, Sweden.

Ghalib MH, Desai KK, Gollamudi R., Chaudhary I., Einstein M., Coffey M., Mettinger K.,

Mani S., Goel S. Dose Escalation and Pharmacodynamic Study of Intravenous

Administration of Reolysin, A Live Replication Competent RNA Virus in Patients with

Advanced Solid Tumors. Poster Presentation at the American Society of Clinical

Oncology 2009 Annual Meeting.

Phaeton R, Wang XG, Einstein MH, Goldberg GL, Casadevall A, Dadachova E. Biodistribution

of 188-Rhenium-labeled antibody to E6 viral protein in experimental cervical tumors _a

potential highly selective tumor-specific treatment for HPV-related cervical cancer.

Poster Presentation at the American Association of Cancer Research 2009 Annual

Meeting.


Kuo DY, Blank SV, Kim M, Caputo TA, Runowicz CD, Pothuri B, Hershman D, Goldman NA,

Ivy P, Muggia F, Goldberg GL, Einstein MH. Paclitaxel Plus Oxaliplatin for Recurrent

or Metastatic Cervical Cancer: A New York Cancer Consortium Study. Focused Plenary

at the 2009 Society of Gynecologic Oncologists Annual Meeting.

Daniel D, Sotardi S, Reimers LL, Chiu LG, Van Arsdale A, Wieland DL, Leider JM, Garry DJ,

Gupta D, Hennessy M, Goldberg GL, Strickler HD, Einstein MH. Are extirpative

procedures effective in women with poorly controlled HIV infection? Alternate Focused

Plenary at the 2009 Society of Gynecologic Oncologists Annual Meeting.

Tugetman J, Reimers LL, Ginsberg MS, Sandesara N, Kuo DY, Einstein MH.

Sociodemographic and HPV Risk Factor Assessment of Early-Adopting Users of the HPV

Vaccine in the Late Catch-Up Population (ages 19-26) in an Ethnically Diverse, Urban

Population. Alternate Focused Plenary at the 2009 Society of Gynecologic Oncologists

Annual Meeting.

Van Doorslaer K, Reimers LL, Studentsov YY, Kadish AS, Goldberg GL, Burk RD, Einstein

MH. E7 Antibody correlative responses identified in women with carcinoma-in-situ who

underwent heat shock protein-based therapeutic vaccination. Poster Presentation at the

2009 Society of Gynecologic Oncologists Annual Meeting.

Yeshchina O, Mehta K, Reimers LL, Hannan R, Milan E, Kalnicki S, Goldberg GL, Einstein

MH, Mutyala S. Feasibility of utilizing PET/CT in radiation therapy treatment planning

for locally advanced cervical cancer. Poster Presentation at the 2009 Society of

Gynecologic Oncologists Annual Meeting.

Gao W, Thawani N, Mutyala S, Phaeton R, Yaparpalvi R, Vainshtein J, Mehta K, Spierer M,

Hannan R, Einstein MH, Kalnicki S. Comparison of early outcomes of concomitant

chemoradiotherapy using intensity modulated radiation therapy versus conventional

radiotherapy for treatment of locally-advanced cervical cancer. Poster Presentation at the

2009 Society of Gynecologic Oncologists Annual Meeting.

Einstein MH, Leanza S, Chiu L, Goldberg GL, Steinberg B, Burk RD. Genetic Variants in TAP

are associated with High-Grade Cervical Neoplasia. Plenary Presentation at the 2008

Society of Gynecologic Oncologists Annual Meeting.

Thawani N, Mutyala S, Saigal K, Yaparpalvi R, Sakaris A, Biagioli M, Einstein M, Goldberg G,

Kalnicki S. Intensity Modulated Radiation Therapy decreases acute toxicity of extended

field radiation with concurrent cisplatin chemotherapy for cervical cancer compared to

Three Dimensional Conformal Radiation Therapy. Plenary Presentation at the 2008

Society of Gynecologic Oncologists Annual Meeting.

Ricky L. Owers, Daniel G. Bamira, Antoinette Sakaris, Christine H. Kim, Gary L. Goldberg,

Dennis Yi-Shin Kuo, Gloria S. Huang, Shohreh Shahabi, Akiva P. Novetsky, Mark H.


Einstein. The Predictive Value of A Drug Resistance Assay in High-Risk Uterine

Cancers: A Pilot Study. Poster Presentation at the 2008 Society of Gynecologic

Oncologists Annual Meeting.

Einstein MH, Leanza S, Chiu L, Goldberg GL, Steinberg BM, Burk RD. Role of Genetic

Variants in TAP for Cervical Cancer Risk. Oral presentation at the 24th

International

Papillomavirus Conference. 2007.

Einstein MH, Chiu L, Allen EM, Zheng K, Ju R, Novetsky AP, Kuo DY, Sakaris A, Podratz

KC, Gostout BL. Pilot Study of The Effectiveness of Cervical Cancer Vaccine-Related

Educational Materials to Improve Willingness to Vaccinate in a Low Socioeconomic

Urban Setting. Poster presentation at the 24th

International Papillomavirus Conference.

2007.

Einstein MH, Chiu L, Allen EM, Ju R, Zheng K, Novetsky AP, Kuo DY, Sakaris A, Podratz

KC, Gostout BL. Effectiveness of Cervical Cancer Vaccine-Related Educational

Materials to Educate in a Low Socioeconomic Urban Setting. Poster Presentation at the

24th

International Papillomavirus Conference. 2007.

Columbo N, McMeekin S, Schwartz P, Kostka J, Sessa C, Gehrig P, Holloway R, Braly P, Matei

D, Einstein M. A Phase 2 Trial of the mTOR inhibitor AP23573 in Advanced

Endometrial Cancer. Poster Discussion presentation at the 2007 ASCO Annual Meeting.


CD. Efficacy of Heat Shock Protein-Based Therapy for Carcinoma-In-Situ of the Cervix.

Poster presentation at the Society of Gynecologic Oncologists 2007 Annual Meeting.

Einstein MH, Testfa L, Caceres A, Goldberg, GL, Kadish, AS. Systemic T Lymphocyte

Responses to HPV 16 E6 and E7 peptides and Local Cervical Inflammatory Changes in

Women with CIN III Treated with Heat Shock Protein-Based Immunotherapy. Poster

presentation at the Society of Gynecologic Oncologists 2007 Annual Meeting.

Prasad L, Einstein MH, Novetsky AP, Goldberg GL, Kuo DY. Is There A Role for Additional

Therapy for Uterine Leiomyosarcoma After Surgery? Poster presentation at the Society of

Gynecologic Oncologists 2007 Annual Meeting.

Einstein MH, Owers RL, Huang GS, Kuo DY, Shahabi S, Fields AL, Goldberg GL. Weekly

Hycamtin and Docetaxel is Efficacious in Heavily Pretreated and Platinum-Resistant

Patients with Recurrent Ovarian and Endometrial Cancers. Poster presentation at the

Society of Gynecologic Oncologists 2007 Annual Meeting.

Tesfa L, Einstein MH, Fennelly G, Burk RD, Kadish AS. T Cell Responses of Women With

Carcinoma In-Situ of The Cervix. Poster presentation of the Cancer Research Institute

Symposium: Cancer Immunology 2006 conference.

Novetsky AP, Garg M, Goldberg GL, Hailpern SM, Fields AL, Horton F, Landau E, Mutyala S,


Einstein MH. Efficacy and toxicity of concomitant cisplatin with external beam

radiotherapy and two brachytherapy insertions for the treatment of locally advanced

cervical cancer. Poster presentation at the Society of Gynecologic Oncologists 2006

Annual Meeting.

Einstein MH, Novetsky AP, Garg M, Hailpern SM, Fields AL, Huang GS, Kalnicki S,

Goldberg GL. Survival and toxicity differences between 5-day and weekly outpatient

cisplatin concomitant chemoradiotherapy regimens in patients with locally advanced

cervical cancer. Plenary presentation at the Society of Gynecologic Oncologists 2006

Annual Meeting.

Huang GS, Gebb J, Einstein MH, Novetsky AP, Fields AL, Goldberg GL. Evaluation of serum

CA125 levels in patients with uterine carcinosarcoma. Poster presentation at the Society

of Gynecologic Oncologists 2006 Annual Meeting.

Fields AL, Gebb J, Einstein MH, Novetsky AP, Goldberg GL. Pilot Phase II Trial of Radiation

“Sandwiched” Between Combination Paclitaxel/Platinum Chemotherapy in Patients

With Uterine Papillary Serous Carcinoma (UPSC). Plenary presentation at the Society of

Gynecologic Oncologists 2006 Annual Meeting.

Weinstock C, Landau E, Gorla G, Einstein MH, Butler J, Kalnicki S, Garg M. Hypofractionated

high dose rate brachytherapy in combination with external beam radiation therapy and

chemotherapy for cervix cancer. Poster presentation at the American Society for

Therapeutic Radiology and Oncology 2005 Conference.

Dar P, Karmin I, Wang A, Einstein MH, Gross SJ. Recurrent uterine arteriovenous

malformation after selective embolization and uneventful delivery. Ultrasound in

Obstetrics and Gynecology. 26(4): 423. 2005. Abstract presented as a free

communication at the International Society of Ultrasound in Obstetrics and Gynecology

(ISUOG) meeting, Vancouver, Canada 2005 (Best free communication award)

Dar P, Gross SJ, Karmin I, Einstein MH. Arteriovenous malformations of the uterus -case series

and a proposed protocol for management. Ultrasound in Obstetrics and Gynecology.

26(4): 319-320. 2005. Oral presentation at the International Society of Ultrasound in

Obstetrics and Gynecology (ISUOG) meeting, Vancouver, Canada 2005

Gonzalez JM, Einstein MH, Fennelly G, Tesfa L, Burk RD, Neefe J, Streicher H, Kadish AS.

HspE7 Immunotherapy Results in Regression of Biopsy-Proven CIN III Lesions and

Enhanced In-Vitro T-Cell Responses to HPV 16 E7 Peptides. Poster presentation at the

2005 International HPV Meeting.


CD. Heat Shock Protein (HSP)-Based Immunotherapy (HspE7) for Treatment of CIN III

(NCI 5850) . Plenary presentation at the Society of Gynecologic Oncologists 2005

Meeting.


Goldberg GL, Sukumvanich P, Einstein MH, Anderson PS, Smith HO, Fields AL. Total Pelvic

Exenterration: Modifications, Trends and Results over 17 years at The Albert Einstein

College of Medicine/Montefiore Medical Center. Plenary presentation at the Society of

Gynecologic Oncologists 2005 Meeting.

Huang GS, Einstein MH, Kandinov L, Sukumvanich P, Sangster C, Fields AL, Goldberg GL.

Single-Institutional Experience Treating Uterine Carcinosarcoma (MMMT). Poster

presentation at the Society of Gynecologic Oncologists 2005 Meeting.

Huang GS, Einstein MH, Hatami M, Sukumvanich P, Tabibian P, Deb N, Fields AL, Goldberg

GL. Predictors of Severe Toxicity in Cervical Cancer Patients Treated with Weekly

Outpatient Cisplatin and Radiation Therapy Including High-Dose-Rate Brachytherapy.

Gynecol Oncol 92: 472. 2004. Poster presentation at the Society of Gynecologic

Oncologists 2004 Meeting.

Sukumvanich P, Einstein MH, Huang GS, Goldberg GL, Fields AL. Tolerability and Toxicity of

Concomitant Cisplatin/RT Administered as Weekly vs. q21 days. Gynecol Oncol 92: 429.

Poster presentation at the Society of Gynecologic Oncologists 2004 Meeting.

Einstein MH, Mohan S, Goldman NA, Swaby LA, Goldberg GL, Fazzari M, Burk RD. Von

Hippel-Lindau Protein and Gene Expression in Endometrial Cancer. Proc Am Assoc

Can Res 2003 44:4274. Poster presentation at the American Association for Cancer

Research 2003 Annual Meeting.

Einstein MH, Studentsov Z, Marks M, Goldberg GL, Fazzari M, Ho G, Kadish A, Runowicz

CD, Burk RD. Papillomavirus-Like Particle Assay to Identify Women At-Risk for

Persistent HPV Infection. Proc Soc Gyn Oncol 2003; A109. Plenary presentation at the

Society of Gynecologic Oncologists 2003 Meeting.

Einstein MH, Parashar B, Sood B, Goldman N, Goldberg GL, Runowicz CD, Anderson PS,

Fields AL. Long-Term Complications of Concomitant Chemoradiotherapy for Locally-

Advanced Cervical Cancer. Proc Soc Gyn Oncol 2002; A139. Poster presentation at the

Society of Gynecologic Oncologists 2002 Meeting.

Einstein MH, Studentsov Z, Marks M, Ho G, Kadish A, Anderson PS, Fields AL, Goldberg GL,

Runowicz CD, Burk RD. Human Papillomavirus-Like Particle Assay for Assessing

Serologic Response to Cervicovaginal HPV 16, 18 and 45 Infection. Proc Soc Gyn Oncol

2002; A138. Abstract presented as a poster presentation for Society of Gynecologic

Oncologists 2002 Meeting. Poster presentation at the American Association for Cancer

Research 2002 Annual Meeting. Abstract presented as an oral presentation at the 2002

Smithkline-Beecham Fellows‟ Forum.

Einstein MH, Khabele D, Goldman N, Zhang Q, Anderson PS, Fields AL, Runowicz CD and

Goldberg GL. Management and Outcome of Advanced Ovarian Cancer in Women Over

75 Years of Age. Proc Am Soc Clin Oncol 2001;20:A2475.


Einstein MH, Cao QJ, Weiss H, Fishman S, Fields AL, Goldberg GL, Runowicz CD, Jones JG,

Anderson PS. Cyclooxygenase-2 Expression in Patients with Endometrial Cancer:

Correlation with other Proliferative Markers and Clinical Prognostic Factors. Poster

presentation at the AACR-NCI-EORTC International Conference on Molecular Targets

and Cancer Therapeutics 2001.

Einstein MH, Studentsov Z, Marks M, Shah S, Ho G, Anderson PS, Fields AL, Runowicz CD,

Goldberg GL, Burk RD. An Improved Assay for Assessing Serologic Response to

Cervicovaginal HPV 16 Infection. Proc Soc of Gyn Oncol 2001; 32:70. Gynecol Oncol

2001; 80 (2):293. Poster presentation at the 2001 Society of Gynecologic Oncologists

Annual Meeting.

Einstein MH, Cao QJ, Weiss H, McElrath T, Fields AL, Goldberg GL, Runowicz CD, Jones JG,

Anderson PS. Expression of Cyclooxygenase-II in Endometrial Cancer In Vivo. Proc Am

Assoc Cancer Res 2001; 42: A4778. Proc Soc of Gyn Oncol 2001; 32:109. Gynecol

Oncol 2001; 80 (2):303. Poster presentation at the American Association for Cancer

Research 2001 Annual Meeting and 2001 Society of Gynecologic Oncologists Annual

Meeting.

Einstein MH, Khabele D, Goldman N, Zhang Q, Anderson PS, Fields AL, Runowicz CD and

Goldberg GL. Management and Outcome of Advanced Ovarian Cancer in Women Over

75 Years of Age. Proc Am Soc Clin Oncol 2001;20:A2475.

Einstein MH, Cruz Y, El-Awady M, Kaplan J, O‟Brien S, DiPaolo J, VanRanst M, Kadish,

A.S., Runowicz CD, Burk RD. Molecular Analysis of Integrated HPV-16 Sequences in

Cervical Cancer. Am Assoc Cancer Res 2000; 41: A2014. Poster discussion

presentation at the American Association for Cancer Research 2000 Annual Meeting.

Timmins PF, Ketz J, Ho GY, Wang Y, He W, Burk RD, Johnson A., Cipriani LA, Einstein MH,

Kadish AS. Cervical Cancer Patients Exhibit Distinct Cellular Immune Responses to

Human Papillomavirus Type 16 E6 and E7 Peptides Compared to Patients with

Intraepithelial Lesions. International HPV Conference Proceedings 2000; 18:A353. Oral

presentation at the International Human Papillomavirus Conference 2000 Meeting.

Einstein MH, Tan D, Williams F, Webster SK. Evaluation of Transfusion Following Acute

Renal Failure. FASEB Proceedings 1989. Poster presentation at the 1989 FASEB

Conference.

Einstein MH, Borgia J, Webster SK. Effect of Protein Restriction on Maximal Reabsorption of

Phosphate in Partially Nephrectomized Rats. FASEB Proceedings 1987. Poster

presentation at the 1987 FASEB Conference.

Page 1 Mark H. Einstein, C.V. CURRICULUM VITAE MARK H ... · CURRICULUM VITAE MARK H. EINSTEIN,...

Documents

Transcript of Page 1 Mark H. Einstein, C.V. CURRICULUM VITAE MARK H ... · CURRICULUM VITAE MARK H. EINSTEIN,...